WO1994029459A1
(en)
*
|
1993-06-04 |
1994-12-22 |
Whitehead Institute For Biomedical Research |
Stress proteins and uses therefor
|
IL102687A
(en)
*
|
1992-07-30 |
1997-06-10 |
Yeda Res & Dev |
Conjugates of poorly immunogenic antigens and synthetic pepide carriers and vaccines comprising them
|
US5736146A
(en)
*
|
1992-07-30 |
1998-04-07 |
Yeda Research And Development Co. Ltd. |
Conjugates of poorly immunogenic antigens and synthetic peptide carriers and vaccines comprising them
|
AUPM322393A0
(en)
*
|
1993-12-24 |
1994-01-27 |
Austin Research Institute, The |
Mucin carbohydrate compounds and their use in immunotherapy
|
US5750119A
(en)
*
|
1994-01-13 |
1998-05-12 |
Mount Sinai School Of Medicine Of The City University Of New York |
Immunotherapeutic stress protein-peptide complexes against cancer
|
US5997873A
(en)
*
|
1994-01-13 |
1999-12-07 |
Mount Sinai School Of Medicine Of The City University Of New York |
Method of preparation of heat shock protein 70-peptide complexes
|
US5961979A
(en)
*
|
1994-03-16 |
1999-10-05 |
Mount Sinai School Of Medicine Of The City University Of New York |
Stress protein-peptide complexes as prophylactic and therapeutic vaccines against intracellular pathogens
|
US5869058A
(en)
*
|
1994-05-25 |
1999-02-09 |
Yeda Research And Development Co. Ltd. |
Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
|
IL109790A0
(en)
*
|
1994-05-25 |
1994-08-26 |
Yeda Res & Dev |
Peptides used as carriers in immunogenic constructs suitable for development of synthetic vaccines
|
GB9422096D0
(en)
*
|
1994-11-02 |
1994-12-21 |
Biocine Spa |
Combined meningitis vaccine
|
US8021667B2
(en)
|
1994-11-16 |
2011-09-20 |
Macfarlane Burnet Institute For Medical Research And Public Health Ltd |
Compositions for immunotherapy and uses thereof
|
US6548643B1
(en)
|
1994-11-16 |
2003-04-15 |
Austin Research Institute |
Antigen carbohydrate compounds and their use in immunotherapy
|
JPH11507214A
(ja)
*
|
1995-06-07 |
1999-06-29 |
バイオケム ヴァシーンズ インク. |
Hsp70ファミリーに属する連鎖球菌の熱ショック蛋白質メンバー
|
US6331299B1
(en)
|
1995-08-18 |
2001-12-18 |
Sloan-Kettering Institute For Cancer Research |
Method for treatment of cancer and infectious disease and compositions useful in same
|
US6761892B1
(en)
|
1995-08-18 |
2004-07-13 |
Sloan-Kettering Institute For Cancer Research |
Heat shock protein-based vaccines and immunotherapies
|
CA2229595A1
(en)
|
1995-08-18 |
1997-02-27 |
Sloan-Kettering Institute For Cancer Research |
Method for treatment of cancer and infectious diseases and compositions useful in same
|
US6719974B1
(en)
|
1995-08-18 |
2004-04-13 |
Sloan-Kettering Institute For Cancer Research |
Heat shock protein-based vaccines and immunotherapies
|
US6773707B1
(en)
|
1995-08-18 |
2004-08-10 |
Sloan-Kettering Institute For Cancer Research |
Heat shock protein-based vaccines and immunotherapies
|
US5837251A
(en)
*
|
1995-09-13 |
1998-11-17 |
Fordham University |
Compositions and methods using complexes of heat shock proteins and antigenic molecules for the treatment and prevention of neoplastic diseases
|
US5935576A
(en)
|
1995-09-13 |
1999-08-10 |
Fordham University |
Compositions and methods for the treatment and prevention of neoplastic diseases using heat shock proteins complexed with exogenous antigens
|
US5985270A
(en)
*
|
1995-09-13 |
1999-11-16 |
Fordham University |
Adoptive immunotherapy using macrophages sensitized with heat shock protein-epitope complexes
|
AU727673B2
(en)
*
|
1995-09-13 |
2000-12-21 |
Fordham University |
Therapeutic and prophylactic methods using heat shock proteins
|
AU1463097A
(en)
*
|
1996-01-04 |
1997-08-01 |
Rican Limited |
Helicobacter pylori bacterioferritin
|
WO1997043649A1
(en)
*
|
1996-05-14 |
1997-11-20 |
Winnacker Ernst Ludwig |
CHARPERONES CAPABLE OF BINDING TO PRION PROTEINS AND DISTINGUISHING THE ISOFORMS PrPc AND PrP?sc¿
|
US7157089B1
(en)
|
1996-11-26 |
2007-01-02 |
Stressgen Biotechnologies Corporation |
Immune responses using compositions containing stress proteins
|
US6017540A
(en)
|
1997-02-07 |
2000-01-25 |
Fordham University |
Prevention and treatment of primary and metastatic neoplastic diseases and infectious diseases with heat shock/stress protein-peptide complexes
|
US5830464A
(en)
|
1997-02-07 |
1998-11-03 |
Fordham University |
Compositions and methods for the treatment and growth inhibition of cancer using heat shock/stress protein-peptide complexes in combination with adoptive immunotherapy
|
EP1047451A1
(de)
*
|
1997-02-18 |
2000-11-02 |
Whitehead Institute For Biomedical Research |
Verwendung von hitzeshockproteinen zur verabreichung von einheiten in zellen
|
ATE327259T1
(de)
|
1997-08-05 |
2006-06-15 |
Stressgen Biotechnologies Corp |
Immunantwort gegen hpv antigene hervorgerufen von zusammensetzungen die ein hpv antigen und ein stressprotein enthalten oder einem expressionsvektor fähig zur expression dieser proteine
|
ES2322212T3
(es)
|
1997-09-29 |
2009-06-17 |
The Macfarlane Burnet Institute For Medical Research And Public Health Ltd |
Composicion de antigeno y linea celular que lleva el receptor manosa.
|
US5948646A
(en)
|
1997-12-11 |
1999-09-07 |
Fordham University |
Methods for preparation of vaccines against cancer comprising heat shock protein-peptide complexes
|
DE69935781T2
(de)
|
1998-02-20 |
2007-12-27 |
University Of Miami, Miami |
Modifizierter hitzeschockprotein/peptidantigen komplex
|
US6497880B1
(en)
|
1998-12-08 |
2002-12-24 |
Stressgen Biotechnologies Corporation |
Heat shock genes and proteins from Neisseria meningitidis, Candida glabrata and Aspergillus fumigatus
|
US6495347B1
(en)
|
1999-07-08 |
2002-12-17 |
Stressgen Biotechnologies Corporation |
Induction of a Th1-like response in vitro
|
ATE438408T1
(de)
*
|
2000-01-14 |
2009-08-15 |
Whitehead Biomedical Inst |
Induktion zytotoxischer lymphozyten durch hitzeschockprotein-fusionsproteine hängt von der atp-bindungsdomäne in hsp ab und is cd4+ unabhängig
|
WO2001091787A1
(en)
|
2000-06-02 |
2001-12-06 |
University Of Connecticut Health Center |
Complexes of alpha (2) macroglobulin and antigenic molecules for immunotherapy
|
PT1296711E
(pt)
|
2000-06-26 |
2006-08-31 |
Stressgen Biotechnologies Corp |
E7 de vph para o tratamento do virus do papiloma humano
|
JP4254931B1
(ja)
|
2000-10-27 |
2009-04-15 |
カイロン ソチエタ ア レスポンサビリタ リミタータ |
A群連鎖球菌およびb群連鎖球菌由来の核酸およびタンパク質
|
US7082569B2
(en)
|
2001-01-17 |
2006-07-25 |
Outlooksoft Corporation |
Systems and methods providing dynamic spreadsheet functionality
|
WO2002062959A2
(en)
|
2001-02-05 |
2002-08-15 |
Stressgen Biotechnologies Corp. |
Hepatitis b virus treatment
|
GB0107661D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Staphylococcus aureus
|
GB0107658D0
(en)
|
2001-03-27 |
2001-05-16 |
Chiron Spa |
Streptococcus pneumoniae
|
GB0115176D0
(en)
|
2001-06-20 |
2001-08-15 |
Chiron Spa |
Capular polysaccharide solubilisation and combination vaccines
|
GB0118249D0
(en)
|
2001-07-26 |
2001-09-19 |
Chiron Spa |
Histidine vaccines
|
GB0121591D0
(en)
|
2001-09-06 |
2001-10-24 |
Chiron Spa |
Hybrid and tandem expression of neisserial proteins
|
WO2003015712A2
(en)
|
2001-08-20 |
2003-02-27 |
University Of Connecticut Health Center |
Methods for preparing compositions comprising heat shock proteins or alpha-2-macroglobulin
|
EP2335724A1
(de)
|
2001-12-12 |
2011-06-22 |
Novartis Vaccines and Diagnostics S.r.l. |
Immunisierung gegen Chlamydia trachomatis
|
JP4646516B2
(ja)
|
2002-02-20 |
2011-03-09 |
ノバルティス バクシンズ アンド ダイアグノスティックス,インコーポレーテッド |
吸着したポリペプチド含有分子を有する微粒子
|
MXPA04011249A
(es)
|
2002-05-14 |
2005-06-06 |
Chiron Srl |
Vacunas mucosales con adyuvante de quitosano y antigenos meningococicos.
|
GB0220194D0
(en)
|
2002-08-30 |
2002-10-09 |
Chiron Spa |
Improved vesicles
|
CA2501812C
(en)
|
2002-10-11 |
2012-07-10 |
Mariagrazia Pizza |
Polypeptide-vaccines for broad protection against hypervirulent meningococcal lineages
|
MY132859A
(en)
|
2002-11-01 |
2007-10-31 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
DK2279746T3
(da)
|
2002-11-15 |
2013-11-25 |
Novartis Vaccines & Diagnostic |
Overfladeproteiner i neisseria meningitidis
|
GB0227346D0
(en)
|
2002-11-22 |
2002-12-31 |
Chiron Spa |
741
|
US8034378B2
(en)
|
2002-12-27 |
2011-10-11 |
Novartis Vaccines And Diagnostics, Inc |
Immunogenic compositions containing phospholipid
|
CA2514328C
(en)
|
2003-01-30 |
2020-01-14 |
Chiron Srl |
Injectable vaccines against multiple meningococcal serogroups
|
US7420037B2
(en)
|
2003-02-13 |
2008-09-02 |
Antigenics Inc. |
Heat shock protein-based vaccines and immunotherapies
|
CA2520124A1
(en)
|
2003-03-28 |
2004-10-14 |
Chiron Corporation |
Use of benzazole compounds for immunopotentiation
|
US7309491B2
(en)
|
2003-04-11 |
2007-12-18 |
Antigenics Inc. |
Heat shock protein-based vaccines and immunotherapies
|
DE602004022286D1
(de)
|
2003-06-02 |
2009-09-10 |
Novartis Vaccines & Diagnostic |
Immunogene zusammensetzungen auf basis von biologisch abbaubaren mikroteilchen enthaltend ein diphtherie- und ein tetanustoxoid
|
CA2540896C
(en)
|
2003-10-02 |
2015-06-02 |
Chiron Srl |
Liquid vaccines for multiple meningococcal serogroups
|
GB0323103D0
(en)
|
2003-10-02 |
2003-11-05 |
Chiron Srl |
De-acetylated saccharides
|
GB0406013D0
(en)
|
2004-03-17 |
2004-04-21 |
Chiron Srl |
Analysis of saccharide vaccines without interference
|
GB0408978D0
(en)
|
2004-04-22 |
2004-05-26 |
Chiron Srl |
Meningococcal fermentation for preparing conjugate vaccines
|
GB0409745D0
(en)
|
2004-04-30 |
2004-06-09 |
Chiron Srl |
Compositions including unconjugated carrier proteins
|
GB0410866D0
(en)
|
2004-05-14 |
2004-06-16 |
Chiron Srl |
Haemophilius influenzae
|
GB0411387D0
(en)
|
2004-05-21 |
2004-06-23 |
Chiron Srl |
Analysis of saccharide length
|
GB0413868D0
(en)
|
2004-06-21 |
2004-07-21 |
Chiron Srl |
Dimensional anlaysis of saccharide conjugates
|
EP1768662A2
(de)
|
2004-06-24 |
2007-04-04 |
Novartis Vaccines and Diagnostics, Inc. |
Immunstimulatoren kleiner moleküle und assays für deren nachweis
|
EP2277595A3
(de)
|
2004-06-24 |
2011-09-28 |
Novartis Vaccines and Diagnostics, Inc. |
Verbindungen zur Immunopotenzierung
|
WO2006078318A2
(en)
|
2004-07-29 |
2006-07-27 |
Novartis Vaccines And Diagnostics Inc. |
Immunogenic compositions for gram positive bacteria such as streptococcus agalactiae
|
GB0424092D0
(en)
|
2004-10-29 |
2004-12-01 |
Chiron Srl |
Immunogenic bacterial vesicles with outer membrane proteins
|
GB0502096D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Purification of streptococcal capsular polysaccharide
|
GB0502095D0
(en)
|
2005-02-01 |
2005-03-09 |
Chiron Srl |
Conjugation of streptococcal capsular saccharides
|
CN101180312A
(zh)
|
2005-02-18 |
2008-05-14 |
诺华疫苗和诊断公司 |
来自尿路病原性大肠杆菌的免疫原
|
SI1858920T1
(sl)
|
2005-02-18 |
2016-07-29 |
Glaxosmithkline Biologicals S.A. |
Proteini in nukleinske kisline iz escherichia coli, povezane z meningitisom/sepso
|
GB0505518D0
(en)
*
|
2005-03-17 |
2005-04-27 |
Chiron Srl |
Combination vaccines with whole cell pertussis antigen
|
JP2008536515A
(ja)
|
2005-04-18 |
2008-09-11 |
ノバルティス ヴァクシンズ アンド ダイアグノスティクス, インコーポレイテッド |
ワクチンの調製のためのb型肝炎ウイルス表面抗原の発現
|
EP1896062B1
(de)
|
2005-06-27 |
2010-03-31 |
GlaxoSmithKline Biologicals S.A. |
Immunogene zusammensetzung
|
CA2621023C
(en)
|
2005-09-01 |
2019-07-02 |
Novartis Vaccines And Diagnostics Gmbh & Co. Kg |
Multiple vaccination including serogroup c meningococcus
|
GB0522303D0
(en)
|
2005-11-01 |
2005-12-07 |
Chiron Srl |
Culture method
|
GB0522765D0
(en)
|
2005-11-08 |
2005-12-14 |
Chiron Srl |
Combination vaccine manufacture
|
EP2360175B1
(de)
|
2005-11-22 |
2014-07-16 |
Novartis Vaccines and Diagnostics, Inc. |
Norovirus und sapovirus virusähnliche partikel (vlps)
|
GB0524066D0
(en)
|
2005-11-25 |
2006-01-04 |
Chiron Srl |
741 ii
|
GB0607088D0
(en)
|
2006-04-07 |
2006-05-17 |
Glaxosmithkline Biolog Sa |
Vaccine
|
NO346529B1
(no)
|
2005-12-22 |
2022-09-26 |
Glaxosmithkline Biologicals Sa |
Bruk av et immunogenpreparat for småbarn, omfattende 22F sakkaridkonjugat
|
US10543265B2
(en)
|
2006-03-22 |
2020-01-28 |
Glaxosmithkline Biologicals Sa |
Regimens for immunisation with meningococcal conjugates
|
GB0605757D0
(en)
|
2006-03-22 |
2006-05-03 |
Chiron Srl |
Separation of conjugated and unconjugated components
|
EP2010537B1
(de)
|
2006-03-23 |
2011-12-28 |
Novartis AG |
Imidazochinoxalinverbindungen als immunmodulatoren
|
US8414899B2
(en)
*
|
2006-04-11 |
2013-04-09 |
Yeda Research And Development Co. Ltd. |
Vaccines comprising multimeric HSP60 peptide carriers
|
ATE522541T1
(de)
|
2006-06-09 |
2011-09-15 |
Novartis Ag |
Bakterielle adhäsine konformere
|
GB0612854D0
(en)
|
2006-06-28 |
2006-08-09 |
Novartis Ag |
Saccharide analysis
|
EP2064230A2
(de)
|
2006-08-16 |
2009-06-03 |
Novartis AG |
Immungene aus uropathogenen escherichia coli
|
PL2066344T3
(pl)
|
2006-09-07 |
2011-10-31 |
Glaxosmithkline Biologicals Sa |
Skojarzona szczepionka zawierająca inaktywowany wirus polio
|
GB0700136D0
(en)
|
2007-01-04 |
2007-02-14 |
Glaxosmithkline Biolog Sa |
Process for manufacturing vaccines
|
GB0700562D0
(en)
|
2007-01-11 |
2007-02-21 |
Novartis Vaccines & Diagnostic |
Modified Saccharides
|
EP2142211A1
(de)
|
2007-05-02 |
2010-01-13 |
GlaxoSmithKline Biologicals S.A. |
Impfstoff
|
SI2167121T1
(sl)
|
2007-06-26 |
2015-12-31 |
Glaxosmithkline Biologicals S.A. |
Cepivo, ki obsega kapsularne polisaharidne konjugate Streptococcusa pneumoniae
|
GB0713880D0
(en)
|
2007-07-17 |
2007-08-29 |
Novartis Ag |
Conjugate purification
|
GB0714963D0
(en)
|
2007-08-01 |
2007-09-12 |
Novartis Ag |
Compositions comprising antigens
|
ES2561483T3
(es)
|
2007-09-12 |
2016-02-26 |
Glaxosmithkline Biologicals Sa |
Antígenos mutantes de GAS57 y anticuerpos de GAS57
|
BRPI0818545A2
(pt)
|
2007-10-19 |
2017-07-04 |
Novartis Ag |
formulações de vacinais meningocócicas
|
GB0818453D0
(en)
|
2008-10-08 |
2008-11-12 |
Novartis Ag |
Fermentation processes for cultivating streptococci and purification processes for obtaining cps therefrom
|
JP5656642B2
(ja)
|
2007-12-21 |
2015-01-21 |
ノバルティス アーゲー |
ストレプトリシンoの変異体形態
|
EP2886551A3
(de)
|
2008-02-21 |
2015-09-23 |
Novartis AG |
Meningokokken-FHBP-Polypeptide
|
CA2717854C
(en)
|
2008-03-03 |
2019-02-19 |
The University Of Miami |
Allogeneic cancer cell-based immunotherapy
|
JP2011515399A
(ja)
|
2008-03-20 |
2011-05-19 |
ユニバーシティー オブ マイアミ |
熱ショックタンパクgp96ワクチン接種及びそれを用いた方法
|
CA2777837C
(en)
|
2008-10-27 |
2017-07-11 |
Novartis Ag |
Purification method
|
GB0822633D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Formulation
|
GB0822634D0
(en)
|
2008-12-11 |
2009-01-21 |
Novartis Ag |
Meningitis vaccines
|
JP2012512240A
(ja)
|
2008-12-17 |
2012-05-31 |
ノバルティス アーゲー |
ヘモグロビン受容体を含む髄膜炎菌ワクチン
|
CN102307477B
(zh)
|
2009-01-05 |
2015-07-29 |
埃皮托吉尼西斯股份有限公司 |
佐剂组合物及使用方法
|
EP2385842A1
(de)
|
2009-01-12 |
2011-11-16 |
Novartis AG |
Cna_b-domänen-antigene in impfstoffen gegen grampositive bakterien
|
DK2411048T3
(da)
|
2009-03-24 |
2020-06-15 |
Glaxosmithkline Biologicals Sa |
Adjuvanterende meningokok-faktor h-bindingsprotein
|
EP3017826A1
(de)
|
2009-03-24 |
2016-05-11 |
Novartis AG |
Kombinationen von meningokkoken-faktor-h-bindenden proteinen und pneumokokken-saccharid-konjugaten
|
NZ612315A
(en)
|
2009-04-14 |
2014-10-31 |
Novartis Ag |
Compositions for immunising against staphylococcus aureus
|
EP2424562B1
(de)
|
2009-04-30 |
2015-10-07 |
Coley Pharmaceutical Group, Inc. |
Pneumokokken-vakzine und deren verwendung
|
US8668911B2
(en)
|
2009-05-14 |
2014-03-11 |
The Regents Of The University Of Michigan |
Streptococcus vaccine compositions and methods of using the same
|
CN104650241A
(zh)
|
2009-08-27 |
2015-05-27 |
诺华股份有限公司 |
包括脑膜炎球菌fHBP序列的杂交多肽
|
PT2473605T
(pt)
|
2009-09-03 |
2018-05-28 |
Pfizer Vaccines Llc |
Vacina pcsk9
|
AU2010293902A1
(en)
|
2009-09-10 |
2012-03-22 |
Novartis Ag |
Combination vaccines against respiratory tract diseases
|
RU2603267C2
(ru)
|
2009-09-30 |
2016-11-27 |
Новартис Аг |
Конъюгация капсульных полисахаридов staphylococcus aureus типа 5 и типа 8
|
CA2776004A1
(en)
|
2009-09-30 |
2011-04-07 |
Novartis Ag |
Expression of meningococcal fhbp polypeptides
|
MX2012004850A
(es)
|
2009-10-27 |
2012-05-22 |
Novartis Ag |
Polipeptidos fhbp meningococicos modificados.
|
HUE034251T2
(en)
|
2009-10-30 |
2018-02-28 |
Glaxosmithkline Biologicals Sa |
Purification of type 5 and type 8 capsular saccharides from Staphylococcus aureus
|
GB0919690D0
(en)
|
2009-11-10 |
2009-12-23 |
Guy S And St Thomas S Nhs Foun |
compositions for immunising against staphylococcus aureus
|
GB201003333D0
(en)
|
2010-02-26 |
2010-04-14 |
Novartis Ag |
Immunogenic proteins and compositions
|
GB201003922D0
(en)
|
2010-03-09 |
2010-04-21 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
GB201005625D0
(en)
|
2010-04-01 |
2010-05-19 |
Novartis Ag |
Immunogenic proteins and compositions
|
WO2011149564A1
(en)
|
2010-05-28 |
2011-12-01 |
Tetris Online, Inc. |
Interactive hybrid asynchronous computer game infrastructure
|
CA2803239A1
(en)
|
2010-06-25 |
2011-12-29 |
Novartis Ag |
Combinations of meningococcal factor h binding proteins
|
GB201101665D0
(en)
|
2011-01-31 |
2011-03-16 |
Novartis Ag |
Immunogenic compositions
|
WO2012072769A1
(en)
|
2010-12-01 |
2012-06-07 |
Novartis Ag |
Pneumococcal rrgb epitopes and clade combinations
|
CA2860331A1
(en)
|
2010-12-24 |
2012-06-28 |
Novartis Ag |
Compounds
|
US10286056B2
(en)
|
2011-01-27 |
2019-05-14 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with crystallisation inhibitors
|
WO2012131504A1
(en)
|
2011-03-02 |
2012-10-04 |
Pfizer Inc. |
Pcsk9 vaccine
|
CA2828844C
(en)
|
2011-03-02 |
2020-07-14 |
Novartis Ag |
Combination vaccines with lower doses of antigen and/or adjuvant
|
GB201103836D0
(en)
|
2011-03-07 |
2011-04-20 |
Glaxosmithkline Biolog Sa |
Conjugation process
|
US10357568B2
(en)
|
2011-03-24 |
2019-07-23 |
Glaxosmithkline Biologicals S.A. |
Adjuvant nanoemulsions with phospholipids
|
EP2511295A1
(de)
|
2011-04-15 |
2012-10-17 |
Institut National De La Sante Et De La Recherche Medicale |
Zusammensetzungen zur Vorbeugung und/oder Behandlung einer Infektion durch einen HIV-1-Virus
|
CN107837394A
(zh)
|
2011-06-24 |
2018-03-27 |
埃皮托吉尼西斯有限公司 |
作为抗原特异性免疫调节剂的包含选择的载体、维生素、单宁和类黄酮的组合的药物组合物
|
WO2013009564A1
(en)
|
2011-07-08 |
2013-01-17 |
Novartis Ag |
Tyrosine ligation process
|
GB201114923D0
(en)
|
2011-08-30 |
2011-10-12 |
Novartis Ag |
Immunogenic proteins and compositions
|
TR201909110T4
(tr)
|
2011-09-14 |
2019-07-22 |
Glaxosmithkline Biologicals Sa |
Sakarit-protein glikokonjugatları yapmaya yönelik yöntemler.
|
EP2776069A1
(de)
|
2011-11-07 |
2014-09-17 |
Novartis AG |
Trägermolekül mit einem spr0096- und einem spr2021-antigen
|
GB2495341B
(en)
|
2011-11-11 |
2013-09-18 |
Novartis Ag |
Fermentation methods and their products
|
DE102011118371B4
(de)
|
2011-11-11 |
2014-02-13 |
Novartis Ag |
Zur Impfung von Menschen geeignete Zusammensetzung, die ein Diphtherie-Toxoid umfasst, sowie Verfahren zu deren Herstellung
|
EP2592137A1
(de)
|
2011-11-11 |
2013-05-15 |
Novartis AG |
Fermentierungsmedium ohne Bestandteile tierischen Ursprungs zur Herstellung von Diphtherie-Impfstoffen zur menschlichen Impfung
|
DE102011122891B4
(de)
|
2011-11-11 |
2014-12-24 |
Novartis Ag |
Fermentationsmedium, das frei von tierischen Bestandteilen ist, zur Herstellung von Diphtherie-Toxoiden zur Verwendung bei der Impfung von Menschen
|
SG11201402375VA
(en)
|
2011-12-08 |
2014-10-30 |
Novartis Ag |
Clostridium difficile toxin-based vaccine
|
GB201121301D0
(en)
|
2011-12-12 |
2012-01-25 |
Novartis Ag |
Method
|
EP2797624A1
(de)
|
2011-12-29 |
2014-11-05 |
Novartis AG |
Kombinationen aus meningokokken-faktor-h-bindenden proteinen
|
MX2014010011A
(es)
|
2012-02-24 |
2014-09-08 |
Novartis Ag |
Proteinas y composiciones de pilus.
|
CN104519910B
(zh)
|
2012-03-07 |
2017-05-03 |
诺华股份有限公司 |
肺炎链球菌抗原的含佐剂制剂
|
WO2013132043A1
(en)
|
2012-03-08 |
2013-09-12 |
Novartis Ag |
Combination vaccines with tlr4 agonists
|
SA115360586B1
(ar)
|
2012-03-09 |
2017-04-12 |
فايزر انك |
تركيبات لعلاج الالتهاب السحائي البكتيري وطرق لتحضيرها
|
US10279026B2
(en)
|
2012-04-26 |
2019-05-07 |
Glaxosmithkline Biologicals Sa |
Antigens and antigen combinations
|
ES2837825T3
(es)
|
2012-04-26 |
2021-07-01 |
Glaxosmithkline Biologicals Sa |
Antígenos y combinaciones de antígenos
|
KR20150021933A
(ko)
|
2012-05-22 |
2015-03-03 |
노파르티스 아게 |
수막염구균 혈청군 x 포합체
|
MX2015002717A
(es)
|
2012-09-06 |
2015-05-15 |
Novartis Ag |
Vacunas combinadas con meningococo del serogrupo b y toxoides de difteria/tetanos/tosferina.
|
JP6266631B2
(ja)
|
2012-10-03 |
2018-01-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
免疫原性組成物
|
SG11201502599TA
(en)
|
2012-10-12 |
2015-05-28 |
Glaxosmithkline Biolog Sa |
Non-cross-linked acellular pertussis antigens for use in combination vaccines
|
RU2018137673A
(ru)
|
2012-11-30 |
2019-03-22 |
Глаксосмитклайн Байолоджикалс Са |
Антигены и комбинации антигенов pseudomonas
|
JP6411378B2
(ja)
|
2013-02-01 |
2018-10-24 |
グラクソスミスクライン バイオロジカルズ ソシエテ アノニム |
Toll様受容体アゴニストを含む免疫学的組成物の皮内送達
|
KR102199096B1
(ko)
|
2013-09-08 |
2021-01-06 |
화이자 인코포레이티드 |
나이세리아 메닌지티디스 조성물 및 그의 방법
|
WO2015095868A1
(en)
|
2013-12-20 |
2015-06-25 |
Wake Forest University Health Sciences |
Methods and compositions for increasing protective antibody levels induced by pneumococcal polysaccharide vaccines
|
HRP20231504T1
(hr)
|
2014-01-21 |
2024-03-01 |
Pfizer Inc. |
Polisaharidi kapsule iz bakterije streptococcus pneumoniae i njihovi konjugati
|
US11160855B2
(en)
|
2014-01-21 |
2021-11-02 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
ES2820824T3
(es)
|
2014-01-21 |
2021-04-22 |
Pfizer |
Composiciones inmunogénicas que comprenden antígenos sacáridos capsulares conjugados y usos de las mismas
|
PT3096783T
(pt)
|
2014-01-21 |
2021-08-16 |
Pfizer |
Polissacáridos capsulares de streptococcus pneumoniae e conjugados dos mesmos
|
ES2930318T3
(es)
|
2014-02-14 |
2022-12-09 |
Pfizer |
Conjugados glucoproteicos inmunogénicos
|
ES2841378T3
(es)
|
2014-02-28 |
2021-07-08 |
Glaxosmithkline Biologicals Sa |
Polipéptidos fHbp meningocócicos modificados
|
EP3034516A1
(de)
|
2014-12-19 |
2016-06-22 |
Novartis AG |
Reinigung von Streptokokkenkapselpolysaccharid
|
BR112017013891B1
(pt)
|
2015-01-15 |
2024-01-30 |
Pfizer Inc |
Composições imunogênicas para uso em vacinas pneumocócicas
|
CN107208099B
(zh)
|
2015-02-06 |
2022-05-13 |
热生物制品有限公司 |
共表达疫苗和共刺激分子的载体
|
WO2016184963A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
WO2016184962A1
(en)
|
2015-05-19 |
2016-11-24 |
Innavirvax |
Treatment of hiv-infected individuals
|
EP3109255A1
(de)
|
2015-06-26 |
2016-12-28 |
Institut National De La Recherche Agronomique |
Immunogene zusammensetzung
|
TWI720448B
(zh)
|
2015-07-21 |
2021-03-01 |
美商輝瑞股份有限公司 |
包含經共軛之莢膜糖抗原的致免疫性組成物、包含該致免疫性組成物之套組及彼等之用途
|
GB201518684D0
(en)
|
2015-10-21 |
2015-12-02 |
Glaxosmithkline Biolog Sa |
Vaccine
|
US10786561B2
(en)
|
2015-11-20 |
2020-09-29 |
Pfizer Inc. |
Immunogenic compositions for use in pneumococcal vaccines
|
KR20180088458A
(ko)
|
2015-12-04 |
2018-08-03 |
다나-파버 캔서 인스티튜트 인크. |
암의 치료를 위한 mica/b 알파 3 도메인의 백신접종
|
WO2017175082A1
(en)
|
2016-04-05 |
2017-10-12 |
Gsk Vaccines S.R.L. |
Immunogenic compositions
|
US10577409B2
(en)
|
2016-05-26 |
2020-03-03 |
Sagabio Co., Ltd. |
Monoclonal antibody inhibiting immunosuppressive functions of pathogens, antigen-binding fragment thereof, and hybridomas producing such antibody
|
DK3254690T3
(da)
|
2016-06-09 |
2020-03-16 |
Sagabio Co Ltd |
Monoklonalt antistof, der hæmmer immunsuppressive funktioner af helicobacter pylori, antigenbindende fragment deraf og hybridomer, der danner dette antistof
|
EP3254732A1
(de)
|
2016-06-09 |
2017-12-13 |
Sagabio Co., Ltd. |
Immunopotenzierende zusammensetzungen, die einen anti helicobacter pylori antikörper enthalten
|
WO2018042015A1
(en)
|
2016-09-02 |
2018-03-08 |
Glaxosmithkline Biologicals Sa |
Vaccines for neisseria gonorrhoeae
|
CN110022893B
(zh)
|
2016-10-07 |
2023-12-29 |
恩特罗姆公司 |
用于癌症疗法的免疫原性化合物
|
WO2018065625A2
(en)
|
2016-10-07 |
2018-04-12 |
Enterome |
Immunogenic compounds for cancer therapy
|
US11666649B2
(en)
|
2016-10-11 |
2023-06-06 |
University Of Miami |
Vectors and vaccine cells for immunity against Zika virus
|
EP3551668A1
(de)
|
2016-12-06 |
2019-10-16 |
GlaxoSmithKline Biologicals S.A. |
Reinigungsverfahren für kaspelpolysaccharid
|
EP3570879B1
(de)
|
2017-01-20 |
2022-03-30 |
Pfizer Inc. |
Immunogene zusammensetzung zur verwendung als pneumokokken-impfstoff
|
EP3577130A2
(de)
|
2017-01-31 |
2019-12-11 |
Pfizer Inc |
Neisseria meningitidis-zusammensetzungen und verfahren dafür
|
KR102650073B1
(ko)
|
2017-01-31 |
2024-03-20 |
머크 샤프 앤드 돔 엘엘씨 |
스트렙토코커스 뉴모니아 혈청형 19f 유래의 협막 다당류 단백질 접합체의 제조 방법
|
CA3058938A1
(en)
|
2017-04-04 |
2018-10-11 |
Heat Biologics, Inc. |
Intratumoral vaccination
|
CA3074708A1
(en)
|
2017-09-07 |
2019-03-14 |
Merck Sharp & Dohme Corp. |
Pneumococcal polysaccharides and their use in immunogenic polysaccharide-carrier protein conjugates
|
CA3084436A1
(en)
|
2017-12-06 |
2019-07-18 |
Merck Sharp & Dohme Corp. |
Compositions comprising streptococcus pneumoniae polysaccharide-protein conjugates and methods of use thereof
|
WO2019197563A2
(en)
|
2018-04-11 |
2019-10-17 |
Enterome S.A. |
Immunogenic compounds for treatment of fibrosis, autoimmune diseases and inflammation
|
SI3773689T1
(sl)
|
2018-04-11 |
2023-02-28 |
Enterome S.A. |
Antigenski peptidi za preprečevanje in zdravljenje raka
|
CA3106291A1
(en)
|
2018-07-19 |
2020-01-23 |
Glaxosmithkline Biologicals Sa |
Processes for preparing dried polysaccharides
|
EP3607967A1
(de)
|
2018-08-09 |
2020-02-12 |
GlaxoSmithKline Biologicals S.A. |
Modifizierte meningokokken fhbp polypeptide
|
US11260119B2
(en)
|
2018-08-24 |
2022-03-01 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
JP2022512345A
(ja)
|
2018-12-12 |
2022-02-03 |
ファイザー・インク |
免疫原性多重ヘテロ抗原多糖-タンパク質コンジュゲートおよびその使用
|
EP3897705A2
(de)
|
2018-12-19 |
2021-10-27 |
Merck Sharp & Dohme Corp. |
Zusammensetzungen mit polysaccharidproteinkonjugaten von streptococcus pneumoniae und verfahren zu deren verwendung
|
WO2020165711A1
(en)
|
2019-02-11 |
2020-08-20 |
Pfizer Inc. |
Neisseria meningitidiscompositions and methods thereof
|
JP7239509B6
(ja)
|
2019-02-22 |
2023-03-28 |
ファイザー・インク |
細菌多糖類を精製するための方法
|
WO2020208502A1
(en)
|
2019-04-10 |
2020-10-15 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens, kits comprising the same and uses thereof
|
MX2021013736A
(es)
|
2019-05-10 |
2021-12-10 |
Glaxosmithkline Biologicals Sa |
Produccion de conjugados.
|
MX2022001241A
(es)
|
2019-07-31 |
2022-04-20 |
Sanofi Pasteur Inc |
Composiciones de conjugados neumococicos multivalentes polisacarido - proteina y metodos para usar los mismos.
|
KR20220069992A
(ko)
|
2019-09-27 |
2022-05-27 |
화이자 인코포레이티드 |
네이세리아 메닌기티디스 조성물 및 그의 방법
|
EP4045150A1
(de)
|
2019-10-16 |
2022-08-24 |
Enterome S.A. |
Immunogene verbindungen zur behandlung von nebennierenkrebs
|
US20230000966A1
(en)
|
2019-11-01 |
2023-01-05 |
Pfizer Inc. |
Escherichia coli compositions and methods thereof
|
DK4021487T3
(da)
|
2019-11-15 |
2024-02-12 |
Enterome S A |
Antigene peptider til forebyggelse og behandling af b-celle malignitet
|
CN114728051A
(zh)
|
2019-11-22 |
2022-07-08 |
葛兰素史克生物有限公司 |
细菌糖糖缀合物疫苗的剂量和施用
|
CA3171864A1
(en)
|
2020-02-21 |
2021-08-26 |
Pfizer Inc. |
Purification of saccharides
|
BR112022014555A2
(pt)
|
2020-02-23 |
2022-09-20 |
Pfizer |
Composições de escherichia coli e métodos das mesmas.
|
US20230250142A1
(en)
|
2020-06-12 |
2023-08-10 |
Glaxosmithkline Biologicals Sa |
Dock tag system
|
GB202013262D0
(en)
|
2020-08-25 |
2020-10-07 |
Glaxosmithkline Biologicals Sa |
Vaccine Composition
|
EP4232593A1
(de)
|
2020-10-22 |
2023-08-30 |
Pfizer Inc. |
Verfahren zur reinigung von bakteriellen polysacchariden
|
MX2023004912A
(es)
|
2020-10-27 |
2023-05-16 |
Pfizer |
Composiciones de escherichia coli y metodos de las mismas.
|
MX2023005221A
(es)
|
2020-11-04 |
2023-05-16 |
Pfizer |
Composiciones inmunogenicas para uso en vacunas neumococicas.
|
US20220202923A1
(en)
|
2020-12-23 |
2022-06-30 |
Pfizer Inc. |
E. coli fimh mutants and uses thereof
|
TW202245835A
(zh)
|
2021-02-04 |
2022-12-01 |
美商默沙東有限責任公司 |
用於肺炎球菌結合物疫苗之奈米乳化液佐劑組合物
|
EP4070814A1
(de)
|
2021-04-07 |
2022-10-12 |
Lama France |
Sars-cov-2-polypeptide und verwendungen davon
|
WO2022234405A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against bacterial and betacoronavirus infections
|
WO2022234416A1
(en)
|
2021-05-03 |
2022-11-10 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
EP4346893A2
(de)
|
2021-05-28 |
2024-04-10 |
Pfizer Inc. |
Immunogene zusammensetzungen mit konjugierten kapselsaccharidantigenen und verwendungen davon
|
CA3221074A1
(en)
|
2021-05-28 |
2022-12-01 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023135515A1
(en)
|
2022-01-13 |
2023-07-20 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2023161817A1
(en)
|
2022-02-25 |
2023-08-31 |
Pfizer Inc. |
Methods for incorporating azido groups in bacterial capsular polysaccharides
|
WO2023187127A1
(en)
|
2022-03-31 |
2023-10-05 |
Enterome S.A. |
Antigenic peptides for prevention and treatment of cancer
|
WO2023218322A1
(en)
|
2022-05-11 |
2023-11-16 |
Pfizer Inc. |
Process for producing of vaccine formulations with preservatives
|
GB202208093D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
GB202208089D0
(en)
|
2022-06-01 |
2022-07-13 |
Glaxosmithkline Biologicals Sa |
Immunogenic composition
|
WO2024084397A1
(en)
|
2022-10-19 |
2024-04-25 |
Pfizer Inc. |
Vaccination against pneumoccocal and covid-19 infections
|
WO2024110827A1
(en)
|
2022-11-21 |
2024-05-30 |
Pfizer Inc. |
Methods for preparing conjugated capsular saccharide antigens and uses thereof
|
US20240181028A1
(en)
|
2022-11-22 |
2024-06-06 |
Pfizer Inc. |
Immunogenic compositions comprising conjugated capsular saccharide antigens and uses thereof
|
WO2024116096A1
(en)
|
2022-12-01 |
2024-06-06 |
Pfizer Inc. |
Pneumococcal conjugate vaccine formulations
|